Compare AstraZeneca plc (AZN) vs Alphabet Inc Class A (GOOGL) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
AstraZeneca plc vs Alphabet Inc Class A — how do they compare? AstraZeneca plc trades at $168.5 (market cap $253.13B), while Alphabet Inc Class A trades at $370.69 (market cap $4.37T). The key difference: Alphabet Inc Class A is far larger — about 17.3× AstraZeneca plc's market cap, and AstraZeneca plc pays the higher dividend (1.92%). Which is the better fit depends on your goals.
| AZN | GOOGL | |
|---|---|---|
Market Cap | $253.13B | $4.37T |
Sector | Health | Media |
52-Week High | $209.48 | $402.62 |
52-Week Low | $137.44 | $182.00 |
Enterprise Value | $279.37B | $4.34T |
Dividend Yield | 1.92% | 0.24% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AstraZeneca (AZN) trades at $169.47, down 1.25% amid recent volatility following a Phase III trial failure for Wainua. The stock shows bearish technical signals with key support at $168 and resistance at $170. Fundamentally, the company reported strong 2025 results with revenue of $58.74B and net income of $10.23B, though a recent $1.5B licensing deal for a lung cancer drug highlights ongoing pipeline investments. Analyst sentiment is mixed with 47.5% buy ratings but recent downgrades from firms like HSBC citing trial setbacks.
The outlook balances robust financials against pipeline execution risks. Revenue growth and high margins support valuation, but the Wainua failure raises concerns about future catalysts. Investors should weigh the company's strong cash flow and market position against clinical trial volatility and potential legal investigations. Near-term price action may hinge on Q2 2026 earnings due July 27, 2026.
Alphabet (GOOGL) trades at $370.92, up 5.22% over the past day, with a neutral technical signal. The company reported strong earnings beats in recent quarters, with Q1 2026 EPS of $5.11 significantly exceeding the $2.64 estimate. Revenue grew to $402.84 billion in 2025, up from $350.0 billion in 2024, while net income increased to $132.17 billion. Analyst sentiment remains overwhelmingly positive, with 85% recommending a buy and a consensus price target of $431.78.
The outlook for GOOGL is positive, driven by robust revenue growth, expanding profit margins, and leadership in AI and cloud infrastructure. Key risks include regulatory scrutiny, competitive pressures in digital advertising, and market volatility. The stock presents a compelling opportunity for growth investors, supported by strong fundamentals and bullish analyst coverage, though investors should be mindful of execution and macroeconomic challenges.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About AstraZeneca plc
A merger between Astra of Sweden and Zeneca Group of the United Kingdom formed AstraZeneca in 1999. The firm sells branded drugs across several major therapeutic classes, including gastrointestinal, diabetes, cardiovascular, respiratory, cancer, and immunology. The majority of sales come from international markets with the United States representing close to one third of its sales.
Read more on AZN →About Alphabet Inc Class A
Alphabet, the parent company of Google, earns nearly 90% of its revenue from Google services, mainly through advertising. Other revenue comes from subscriptions (YouTube TV, YouTube Music), platform sales (Play Store purchases), and devices (Pixel, Chromebooks, Chromecast). Google Cloud contributes around 10%, while investments in self-driving cars (Waymo), health (Verily), and internet access (Google Fiber) make up the rest.
Read more on GOOGL →
